{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:30:34Z","timestamp":1793255434638,"version":"4.5.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Posaconazole (POSA), a second-generation triazole antifungal drug, inhibits CYP3A and P-glycoprotein. Here, the interaction between POSA and tacrolimus (TAC) in patients undergoing early renal transplantation was studied.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Twenty-two renal transplant recipients who received POSA as antifungal therapy were studied. The following indicators were analyzed statistically: the blood concentration (<jats:italic toggle=\"yes\">C<\/jats:italic>), dose (<jats:italic toggle=\"yes\">D<\/jats:italic>), and concentration\u2013dose ratio (<jats:italic toggle=\"yes\">C\/D<\/jats:italic>) of TAC before and after introducing POSA; the change of <jats:italic toggle=\"yes\">C\/D<\/jats:italic> (\u0394<jats:italic toggle=\"yes\">C\/D<\/jats:italic>) after starting POSA; the genotypes of CYP3A5*3, ABCB1 3435, ABCB1 1236, and POR*28; other routine clinical indicators.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>After starting POSA, the <jats:italic toggle=\"yes\">C<\/jats:italic>, <jats:italic toggle=\"yes\">D<\/jats:italic>, and <jats:italic toggle=\"yes\">C\/D<\/jats:italic> values of TAC were 1.29, 0.57, and 2.74 times the original values, respectively. A linear correlation was observed between the plasma levels of POSA and \u0394<jats:italic toggle=\"yes\">C<\/jats:italic>\/<jats:italic toggle=\"yes\">D<\/jats:italic>. The CYP3A5*3 gene polymorphism showed a significant impact on <jats:italic toggle=\"yes\">C<\/jats:italic>, <jats:italic toggle=\"yes\">D<\/jats:italic>, and <jats:italic toggle=\"yes\">C\/D<\/jats:italic> of TAC; however, it did not affect the \u0394<jats:italic toggle=\"yes\">C\/D<\/jats:italic>. Polymorphism of the ABCB1 3435 gene had a significant effect on \u0394<jats:italic toggle=\"yes\">C\/D<\/jats:italic>, and patients with the CC genotype in ABCB1 3435 had significantly lower \u0394<jats:italic toggle=\"yes\">C\/D<\/jats:italic> than the CT\/TT patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>In renal transplant patients, considerable interindividual variability was observed in the drug interactions between POSA and TAC. The genotypes of CYP3A5*3 and ABCB1 3435 and the plasma level of POSA had strong impact on the interaction between POSA and TAC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001272","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T20:00:10Z","timestamp":1731700810000},"page":"330-336","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Gene Polymorphisms Play an Important Role in the Drug Interaction Between Posaconazole and Tacrolimus in Renal Transplant Patients"],"prefix":"10.1097","volume":"47","author":[{"given":"Nan","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Third Affiliated Hospital of Soochow University, Changzhou;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengmeng","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Third Affiliated Hospital of Soochow University, Changzhou;"},{"name":"College of Pharmaceutical Sciences, Soochow University, Suzhou;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Gu","sequence":"additional","affiliation":[{"name":"Suzhou Medical College, Soochow University, Suzhou;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuping","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Third Affiliated Hospital of Soochow University, Changzhou;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Third Affiliated Hospital of Soochow University, Changzhou;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Zhao","sequence":"additional","affiliation":[{"name":"School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Third Affiliated Hospital of Soochow University, Changzhou;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingting","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,11,15]]},"reference":[{"key":"R1-20250509","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.3760\/cma.j.issn.0366-6999.20140518","article-title":"Effects of tacrolimus and cyclosporine treatment on metabolic syndrome and cardiovascular risk factors after renal transplantation: a meta-analysis","volume":"127","author":"Xue","year":"2014","journal-title":"Chin Med J (Engl)."},{"key":"R2-20250509","doi-asserted-by":"crossref","first-page":"21207","DOI":"10.1038\/s41598-022-25445-2","article-title":"Calcineurin inhibitors' impact on cardiovascular and renal function, a descriptive study in lung transplant recipients from the North of Spain","volume":"12","author":"Nogueiras-\u00c1lvarez","year":"2022","journal-title":"Sci Rep."},{"key":"R3-20250509","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2174\/1389200219666180129151948","article-title":"Pharmacokinetics, pharmacodynamics and pharmacogenetics of tacrolimus in kidney transplantation","volume":"19","author":"Yu","year":"2018","journal-title":"Curr Drug Metab."},{"key":"R4-20250509","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther Drug Monit."},{"key":"R5-20250509","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1586\/1744666X.2016.1123093","article-title":"Tacrolimus for the prevention and treatment of rejection of solid organ transplants","volume":"12","author":"Scalea","year":"2016","journal-title":"Expert Rev Clin Immunol."},{"key":"R6-20250509","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.pharmthera.2006.04.006","article-title":"An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients","volume":"112","author":"Masuda","year":"2006","journal-title":"Pharmacol Ther."},{"key":"R7-20250509","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/FPC.0b013e328307c26e","article-title":"Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients","volume":"18","author":"Kuypers","year":"2008","journal-title":"Pharmacogenet Genomics."},{"key":"R8-20250509","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/17425255.2020.1764939","article-title":"Posaconazole in prophylaxis and treatment of invasive fungal infections: a pharmacokinetic, pharmacodynamic and clinical evaluation","volume":"16","author":"Van Daele","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R9-20250509","first-page":"63","article-title":"Metabolism and drug-drug interaction of tacrolimus, cyclosporine and triazole antifungal","volume":"28","author":"Pu","year":"2019","journal-title":"Chin J Nephrol Dial Transpl."},{"key":"R10-20250509","first-page":"2093","article-title":"Simultaneous determination ofconcentration of six antifungal drugs in human plasma by LC-MS\/MS","volume":"38","author":"Yang","year":"2021","journal-title":"Chin J Mod Appl Pharm."},{"key":"R11-20250509","first-page":"65","article-title":"Effect of CYP3A5 and POR gene polymorphisms on dosage and concentration of tacrolimus in renal transplant patients during hospital stay","volume":"40","author":"Hu","year":"2020","journal-title":"Chin J Hosp Pharm."},{"key":"R12-20250509","first-page":"489","article-title":"Effect of CYP3A5 and ABCB1 gene polymorphism on dosage and concentration of tacrolimus and renal function in renal transplant recipients at early postoperative period","volume":"17","author":"Hu","year":"2019","journal-title":"Cent South Pharm"},{"key":"R13-20250509","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00134-019-05597-y","article-title":"Diagnostic and therapeutic approach to infectious diseases in solid organ transplant recipients","volume":"45","author":"Timsit","year":"2019","journal-title":"Intensive Care Med."},{"key":"R14-20250509","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3390\/jof9020144","article-title":"Systemic antifungal therapy for invasive pulmonary infections","volume":"9","author":"Ben-Ami","year":"2023","journal-title":"J Fungi"},{"key":"R15-20250509","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3109\/00498254.2011.631224","article-title":"Effect of voriconazole and other azole antifungal agents on CYP3A activity and metabolism of tacrolimus in human liver microsomes","volume":"42","author":"Zhang","year":"2012","journal-title":"Xenobiotica"},{"key":"R16-20250509","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/00498254.2018.1473662","article-title":"The impact of azole antifungal drugs on imatinib metabolism in human liver microsomes","volume":"49","author":"Luo","year":"2019","journal-title":"Xenobiotica"},{"key":"R17-20250509","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/17425255.2012.639360","article-title":"Effect of posaconazole on the pharmacokinetics of simvastatin and midazolam in healthy volunteers","volume":"8","author":"Krishna","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R18-20250509","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/tid.12751","article-title":"Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4","volume":"19","author":"Groll","year":"2017","journal-title":"Transpl Infect Dis."},{"key":"R19-20250509","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s40265-020-01306-y","article-title":"Pharmacokinetics and pharmacodynamics of posaconazole","volume":"80","author":"Chen","year":"2020","journal-title":"Drugs"},{"key":"R20-20250509","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.21037\/atm-21-4124","article-title":"Effects of voriconazole on population pharmacokinetics and optimization of the initial dose of tacrolimus in children with chronic granulomatous disease undergoing hematopoietic stem cell transplantation","volume":"9","author":"Chen","year":"2021","journal-title":"Ann Transl Med."},{"key":"R21-20250509","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1111\/ajt.14232","article-title":"Determinants of the magnitude of interaction between tacrolimus and voriconazole\/posaconazole in solid organ recipients","volume":"17","author":"Vanhove","year":"2017","journal-title":"Am J Transpl."},{"key":"R22-20250509","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.3390\/pharmaceutics14122739","article-title":"The effect of voriconazole on tacrolimus in kidney transplantation recipients: a real-world study","volume":"14","author":"Zhao","year":"2022","journal-title":"Pharmaceutics"},{"key":"R23-20250509","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/FTD.0b013e31819de6fd","article-title":"Safe management of tacrolimus together with posaconazole in lung transplant patients with cystic fibrosis","volume":"31","author":"Berge","year":"2009","journal-title":"Ther Drug Monit."},{"key":"R24-20250509","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1078155219833440","article-title":"The impact of initiating posaconazole on tacrolimus pharmacokinetics in allogeneic stem cell transplantation","volume":"26","author":"Collins","year":"2020","journal-title":"J Oncol Pharm Pract."},{"key":"R25-20250509","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1177\/10781552211029046","article-title":"Comparative effects of fluconazole, posaconazole, and isavuconazole upon tacrolimus and cyclosporine serum concentrations","volume":"28","author":"Gu","year":"2022","journal-title":"J Oncol Pharm Pract."},{"key":"R26-20250509","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1592\/phco.27.6.825","article-title":"Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus","volume":"27","author":"Sansone\u2010Parsons","year":"2007","journal-title":"Pharmacother J Hum Pharmacol Drug Ther."},{"key":"R27-20250509","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40262-013-0120-3","article-title":"The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation","volume":"53","author":"Hesselink","year":"2014","journal-title":"Clin Pharmacokinet."},{"key":"R28-20250509","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.3390\/ijms21072287","article-title":"Influence of POR*28 polymorphisms on CYP3A5*3-associated variations in tacrolimus blood levels at an early stage after liver transplantation","volume":"21","author":"Nakamura","year":"2020","journal-title":"Int J Mol Sci."},{"key":"R29-20250509","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2174\/1389200223666220516094226","article-title":"Impact of POR*28 variant on tacrolimus pharmacokinetics in kidney transplant patients with different CYP3A5 genotypes","volume":"23","author":"Everton","year":"2022","journal-title":"Curr Drug Metab."},{"key":"R30-20250509","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ejmhg.2016.10.005","article-title":"Effect of ABCB1 (3435C>T) and CYP3A5 (6986A>G) genes polymorphism on tacrolimus concentrations and dosage requirements in liver transplant patients","volume":"18","author":"Helal","year":"2017","journal-title":"Egypt J Med Hum Genet."},{"key":"R31-20250509","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1515\/CCLM.2006.229","article-title":"The influence of genetic polymorphisms of cytochrome P450 3A5 and ABCB1 on starting dose- and weight-standardized tacrolimus trough concentrations after kidney transplantation in relation to renal function","volume":"44","author":"Mourad","year":"2006","journal-title":"Clin Chem Lab Med."},{"key":"R32-20250509","first-page":"1093","article-title":"Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients","volume":"28","author":"Provenzani","year":"2011","journal-title":"Int J Mol Med."},{"key":"R33-20250509","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2217\/pgs.15.165","article-title":"Donor ABCB1 3435 C>T genetic polymorphisms influence early renal function in kidney transplant recipients treated with tacrolimus","volume":"17","author":"Yan","year":"2016","journal-title":"Pharmacogenomics"},{"key":"R34-20250509","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.transproceed.2013.02.055","article-title":"Effect of MDR1 Polymorphisms on the blood concentrations of tacrolimus in Turkish renal transplant patients","volume":"45","author":"Ciftci","year":"2013","journal-title":"Transpl Proc"},{"key":"R35-20250509","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.2146\/ajhp080396","article-title":"Effect of the ABCB1 3435C>T polymorphism on tacrolimus concentrations and dosage requirements in liver transplant recipients","volume":"66","author":"Bonhomme-Faivre","year":"2009","journal-title":"Am J Health Syst Pharm."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001272","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T12:00:25Z","timestamp":1746792025000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001272","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,15]]},"assertion":[{"value":"2024-07-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}